Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | XTX202 |
| Synonyms | |
| Therapy Description |
XTX202 is a modified variant of IL-2 that once unmasked binds to IL-2Rbeta, but does not bind to IL-2Ralpha, and potentially inhibits tumor growth (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 2563-2563). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| XTX202 | XTX-202|XTX 202 | XTX202 is a modified variant of IL-2 that once unmasked binds to IL-2Rbeta, but does not bind to IL-2Ralpha, and potentially inhibits tumor growth (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 2563-2563). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05052268 | Phase Ib/II | XTX202 | XTX202 in Patients With Advanced Solid Tumors | Completed | USA | 0 |